Literature DB >> 25066492

Use of healthcare resources and costs of acute cardioembolic stroke management in the Region of Madrid: The CODICE Study.

F de Andrés-Nogales1, J Vivancos Mora2, F J Barriga Hernández3, F Díaz Otero4, L Izquierdo Esteban5, M Á Ortega-Casarrubios6, L Castillo Moreno3, Á Ximénez-Carrillo Rico2, M P Martín Torres4, C I Gómez-Escalonilla Escobar5, C Torres González7, M de Salas-Cansado8, M Á Casado Gómez7, J Soto Álvarez8, A Gil-Núñez4.   

Abstract

INTRODUCTION: Stroke is the main cause of admission to Neurology departments and cardioembolic stroke (CS) is one of the most common subtypes of stroke.
METHODS: A multicentre prospective observational study was performed in 5 Neurology departments in public hospitals in the Region of Madrid (Spain). The objective was to estimate the use of healthcare resources and costs of acute CS management. Patients with acute CS at<48h from onset were recruited. Patients' socio-demographic, clinical, and healthcare resource use data were collected during hospitalisation and at discharge up to 30 days after admission, including data for rehabilitation treatment after discharge.
RESULTS: During an 8-month recruitment period, 128 patients were recruited: mean age, 75.3±11.25; 46.9% women; mortality rate, 4.7%. All patients met the CS diagnostic criteria established by GEENCV-SEN, based on medical history or diagnostic tests. Fifty per cent of the patients had a history of atrial fibrillation and 18.8% presented other major cardioembolic sources. Non-valvular atrial fibrillation was the most frequent cause of CS (33.6%). Data for healthcare resource use, given a mean total hospital stay of 10.3±9.3 days, are as follows: rehabilitation therapy during hospital stay (46.9%, mean 4.5 days) and after discharge (56.3%, mean 26.8 days), complications (32%), specific interventions (19.5%), and laboratory and diagnostic tests (100%). Head CT (98.4%), duplex ultrasound of supra-aortic trunks (87.5%), and electrocardiogram (85.9%) were the most frequently performed diagnostic procedures. Average total cost per patient during acute-phase management and rehabilitation was €13,139. Hospital stay (45.0%) and rehabilitation at discharge (29.2%) accounted for the largest part of resources used.
CONCLUSIONS: Acute CS management in the Region of Madrid resulted consumes large amounts of resources (€13,139), mainly due to hospital stays and rehabilitation.
Copyright © 2014 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cardioembolic stroke; Comunidad de Madrid; Costes; Costs; Ictus; Infarto cerebral cardioembólico; Region of Madrid (Spain); Resource use; Sanidad Pública; Spanish National Health System; Stroke; Utilización de recursos

Mesh:

Year:  2014        PMID: 25066492     DOI: 10.1016/j.nrl.2014.06.002

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  4 in total

1.  A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective.

Authors:  Steve Ryder; Kathleen Fox; Pratik Rane; Nigel Armstrong; Ching-Yun Wei; Sohan Deshpande; Lisa Stirk; Yi Qian; Jos Kleijnen
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

2.  Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients.

Authors:  Elizabeth Parody-Rua; Alejandro Bustamante; Joan Montaner; Maria Rubio-Valera; David Serrano; Soledad Pérez-Sánchez; Alba Sánchez-Viñas; César Guevara-Cuellar; Antoni Serrano-Blanco
Journal:  Eur J Health Econ       Date:  2022-07-27

3.  Cost-effectiveness of mechanical thrombectomy using stent retriever after intravenous tissue plasminogen activator compared with intravenous tissue plasminogen activator alone in the treatment of acute ischaemic stroke due to large vessel occlusion in Spain.

Authors:  Fernando de Andrés-Nogales; María Álvarez; María Ángeles de Miquel; Tomás Segura; Alberto Gil; Pere Cardona; Miguel Ángel Casado; Raul G Nogueira; Antoni Dávalos
Journal:  Eur Stroke J       Date:  2017-08-01

4.  Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention.

Authors:  Itziar Oyagüez; Carmen Suárez; José Luis López-Sendón; José Ramón González-Juanatey; Fernando de Andrés-Nogales; Jorge Suárez; Carlos Polanco; Javier Soto
Journal:  Pharmacoecon Open       Date:  2020-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.